Posts

Kura Reports Durable Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve ccRCC at KCRS 2026

on

Yarrow begins trading as it advances Graves’ disease and thyroid eye disease program

on

MapLight's schizophrenia drug dampens once‑daily hopes despite Phase 2 win

on

Legend Biotech CEO Ying Huang Resigns

on

AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease

on

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

on

Leerink Partners Report Names Carterra a Core Enabler of the $7B 'Lab-in-the-Loop' Antibody Discovery Market

on

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

on

AZ stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss

on

MapLight shares sink on mixed Phase 2 schizophrenia readout

on

FDA Approves Otsuka's Tool SIMTRIYO

on

Argenx Acquires Forte Biosciences for $2.2 Billion to Add Phase 2‑Stage Vitiligo and Celiac Drug FB102 to Its Immunology Pipeline

on

Sarepta Taps Former AbbVie and Tessera CEO Michael Severino as New CEO to Lead Duchenne Drugmaker's Turnaround

on